SCHEMBL23587102

SCHEMBL23587102

CCC(C)c1ncn2ccccc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
MIF P14174 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALDH1A1 P00352 3/20 0.32
APLNR P35414 2/20 0.32
APAF1 O14727 1/20 0.31
PDE5A O76074 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
PDE4A P27815 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25584288 0.85 POLB (0.34) TSHRSMN1; SMN2LMNAHTTMIF
SCHEMBL17248114 0.84 PDE4B (0.41) TSHRMIFMEN1KMT2AHPGD
SCHEMBL25533950 0.81 MEN1 (0.34) TSHRMIFMEN1KMT2AHPGD
SCHEMBL23382287 0.80 SLC6A2 (0.33) APLNRDRD4
SCHEMBL24984389 0.77 LMNA (0.33) SMN1; SMN2LMNAKMT2AALDH1A1RAB9A
SCHEMBL24983717 0.75 LMNA (0.32) SMN1; SMN2LMNAALDH1A1
SCHEMBL22607382 0.73 CDK4 (0.36) TSHRSMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL24983903 0.73 PIK3CG (0.35) HPGDALDH1A1
SCHEMBL11155397 0.72 DRD4 (0.40) SMN1; SMN2LMNAMEN1KMT2AHPGD
SCHEMBL11166846 0.71 DRD4 (0.38) TSHRSMN1; SMN2LMNAMIFMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673886-B2 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-13 US disclosed
EP-3652168-B1 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673886-B2 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK MYLK, ROCK1, ROCK2 TSHR 2862/4885SMN1; SMN2 990/4885LMNA 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.